Search research articles
Contact Us
Filters
Showing results (31-40 of 438) with videos related to
Page
of 44
Sort By:
BMC Medicine
|
April 23, 2011
Circulating tumor cells in breast cancer: a tool whose time has come of age
Ramona F Swaby, Massimo Cristofanilli
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 14, 2011
Circulating tumor cells and PET
Jian Q Yu, Massimo Cristofanilli
Seminars in Radiation Oncology
|
September 8, 2009
Inflammatory breast cancer
Wendy A Woodward, Massimo Cristofanilli
Future Oncology (London, England)
|
March 28, 2006
The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer
Charles H Yang, Massimo Cristofanilli
The Journal of Liquid Biopsy
|
April 6, 2026
Advancing clinical integration of circulating tumor cells: Outcomes of an international expert consensus
Massimo Cristofanilli, M Jose Serrano
Journal of the National Cancer Institute
|
June 11, 2009
Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells
Daniel F Hayes, Massimo Cristofanilli
Current Treatment Options in Oncology
|
February 16, 2017
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Ami N Shah, Massimo Cristofanilli
Seminars in Oncology
|
March 1, 2008
Defining the clinical diagnosis of inflammatory breast cancer
S Eva Singletary, Massimo Cristofanilli
The Oncologist
|
July 22, 2004
Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective
Massimo Cristofanilli, Gabriel N Hortobágyi
JAMA Oncology
|
July 10, 2020
Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer: Positive, Negative, or a More Complex Issue?
Andrew A Davis, Massimo Cristofanilli
Page
of 44
Search research articles
Search
Showing results (31-40 of 438) with videos related to
Sort By:
Page
of 44
BMC Medicine
|
April 23, 2011
Circulating tumor cells in breast cancer: a tool whose time has come of age
Ramona F Swaby, Massimo Cristofanilli
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 14, 2011
Circulating tumor cells and PET
Jian Q Yu, Massimo Cristofanilli
Seminars in Radiation Oncology
|
September 8, 2009
Inflammatory breast cancer
Wendy A Woodward, Massimo Cristofanilli
Future Oncology (London, England)
|
March 28, 2006
The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer
Charles H Yang, Massimo Cristofanilli
The Journal of Liquid Biopsy
|
April 6, 2026
Advancing clinical integration of circulating tumor cells: Outcomes of an international expert consensus
Massimo Cristofanilli, M Jose Serrano
Journal of the National Cancer Institute
|
June 11, 2009
Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells
Daniel F Hayes, Massimo Cristofanilli
Current Treatment Options in Oncology
|
February 16, 2017
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Ami N Shah, Massimo Cristofanilli
Seminars in Oncology
|
March 1, 2008
Defining the clinical diagnosis of inflammatory breast cancer
S Eva Singletary, Massimo Cristofanilli
The Oncologist
|
July 22, 2004
Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective
Massimo Cristofanilli, Gabriel N Hortobágyi
JAMA Oncology
|
July 10, 2020
Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer: Positive, Negative, or a More Complex Issue?
Andrew A Davis, Massimo Cristofanilli
Page
of 44